BioAtla (BCAB) Long-Term Debt Issuances (2020)

BioAtla (BCAB) posted quarterly Long-Term Debt Issuances of $2.2 million for Q2 2020, up 350.0% quarter-over-quarter from $500000.0 in Q1 2020.

BioAtla (BCAB) Long-Term Debt Issuances (2020) Analysis & Trends

BioAtla's Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $2.2 million for Q2 2020.

In Q2 2020, Long-Term Debt Issuances changed N/A year-over-year to $2.2 million; the TTM figure through Mar 2021 stood at $2.2 million (changed N/A YoY), while the FY2020 annual figure was $2.8 million, down 31.25% from the prior year.
Long-Term Debt Issuances for Q2 2020 stood at $2.2 million, up from $500000.0 in the prior quarter.
The five-year high for Long-Term Debt Issuances was $2.2 million in Q2 2020, with the low at $500000.0 in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	BioAtla	5.41 Mn	5.41 Mn	-	-

Download Data